Levy Dylan A, Patel Jaimin J, Nguyen Shaun A, Nicholas Jungbauer W, Neskey David M, Cohen Ezra E W, Paulos Chrystal M, Kaczmar John A, Knochelmann Hannah M, Day Terry A
Department of Otolaryngology-Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA.
Department of Cell and Molecular Pharmacology and Developmental Therapeutics Medical University of South Carolina Charleston South Carolina USA.
World J Otorhinolaryngol Head Neck Surg. 2022 Apr 18;8(3):177-186. doi: 10.1002/wjo2.15. eCollection 2022 Sep.
PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).
Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).
Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.
Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.
PD-1和PD-L1抑制剂已成为头颈部鳞状细胞癌（HNSCC）患者有前景的治疗方法。
对头颈部鳞状细胞癌中PD-1和PD-L1抑制剂进行系统评价和荟萃分析。结局指标：总生存中位数（mOS）、无进展生存中位数（mPFS）、实体瘤疗效评价标准（RECIST）和治疗相关不良事件（TRAEs）。
11项试验报告了1088例患者的数据（平均年龄：59.9岁，范围：18 - 90岁）。总mOS为7.97个月（范围：6.0 - 16.5）。所有研究的平均mPFS为2.84个月（范围：1.9 - 6.5）。PD-1抑制剂的RECIST疾病进展率低于PD-L1抑制剂（42.61%，95%置信区间[CI]：36.29 - 49.06 vs. 56.79%，95% CI：49.18 - 64.19，P < 0.001）。任何级别的TRAEs发生率（62.7%，95% CI：59.8 - 65.6）无差异。
荟萃分析显示了PD-1和PD-L1抑制剂在头颈部鳞状细胞癌中的疗效，并提示PD-1和PD-L1抑制剂在某些RECIST标准上可能存在差异。有必要开展进一步研究以探究这些发现的临床意义。
